Compare Crispr Therapeutics AG (CRSP) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Nu Holdings Ltd — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Nu Holdings Ltd trades at $16.12 (market cap $74.30B). The key difference: Nu Holdings Ltd is far larger — about 15.2× Crispr Therapeutics AG's market cap, and Nu Holdings Ltd is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Nu Holdings Ltd for 53 Days on average.
| CRSP | NU | |
|---|---|---|
Market Cap | $4.88B | $74.30B |
Volume | 2,861,747 | 80,294,805 |
Sector | Health | Financials |
52-Week High | $73.97 | $18.76 |
52-Week Low | $44.34 | $11.60 |
Typical Hold Time | 77 Days | 53 Days |
Enterprise Value | $3.30B | $96.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
NU Holdings Ltd. (NU) is trading at $15.38, down 1.28% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company demonstrates strong fundamental growth, with revenue increasing from $3.0B in 2022 to $10.63B in 2025 and net income turning positive to $2.87B. Recent news highlights market volatility around acquisition speculation, but the core business in Brazilian digital banking remains robust.
The outlook for NU is positive, supported by rapid customer growth and expanding profitability, though risks include credit concentration and integration challenges from potential acquisitions. Analyst consensus is bullish with a $16.53 price target, suggesting potential upside from the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
